scholarly journals First brachytherapy treatment of prostate cancer in Nigeria using low dose rate radioactive iodine 125

2020 ◽  
Vol 26 (1) ◽  
Author(s):  
Oludare Folajimi Adeyemi ◽  
Rachid Mghari
Keyword(s):  
Prostate Cancer ◽  
Dose Rate ◽  
Low Dose ◽  
Radioactive Iodine ◽  
Specific Antigen ◽  
Risk Category ◽  
Prostate Brachytherapy ◽  
Total Blood ◽  
Low Dose Rate ◽  
Iodine 125

Abstract Background We report the first prostate brachytherapy in Nigeria, using low dose radioactive iodine 125 (I-125) permanent seeds implant. Case Presentation The low dose rate brachytherapy using I-125 implants was performed in a private clinic in the city of Benin, Edo state of Nigeria. This pilot study reports the case of the first two patients with prostate cancer. The patients were treated under spinal anesthesia using 2 ml of heavy bupibacaine which is equivalent to 10 mg of bupibacaine. Biopsy, total blood count, electrolytes, urea, creatinine, urinalysis, electrocardiogram, chest X-ray, prostate-specific antigen and bone scan were checked prior to the procedure. The first two prostate cancer patients who were in low risk category successfully received the treatment in the first day of the clinic’s operations. This paper describes the settings in which these clinical operations occurred, detailing the type of technology used, the clinical procedure and the obtained dose distribution. Conclusions The paper ends with discussing the overall cost of the investment and the challenges encountered as well as the perspectives of extending the brachytherapy practice to treat other cancer diseases, such as breast and genealogical cancers.

scholarly journals Enhanced activated T�cell subsets in prostate cancer patients receiving iodine-125 low-dose-rate prostate brachytherapy

2017 ◽  
Author(s):  
Makoto Kubo ◽  
Takefumi Satoh ◽  
Hiromichi Ishiyama ◽  
Ken-Ichi Tabata ◽  
Hideyasu Tsumura ◽  
...  
Keyword(s):  
Prostate Cancer ◽  
Dose Rate ◽  
Cancer Patients ◽  
Low Dose ◽  
Prostate Brachytherapy ◽  
Low Dose Rate ◽  
Iodine 125

Placement of Space OAR hydrogel spacer for prostate cancer patients treated with iodine‐125 low‐dose‐rate brachytherapy

2019 ◽  
Vol 27 (1) ◽  
pp. 60-66 ◽  
Author(s):  
Masashi Morita ◽  
Takashi Fukagai ◽  
Kidai Hirayama ◽  
Jin Yamatoya ◽  
Tetsuo Noguchi ◽  
...  
Keyword(s):  
Prostate Cancer ◽  
Dose Rate ◽  
Cancer Patients ◽  
Low Dose ◽  
Low Dose Rate ◽  
Iodine 125 ◽  
Low Dose Rate Brachytherapy

Preliminary results of a study on focal low dose rate prostate brachytherapy using Cesium 131.

2018 ◽  
Vol 36 (6_suppl) ◽  
pp. 151-151
Author(s):  
Brian Joseph Moran ◽  
Michelle H. Braccioforte
Keyword(s):  
Prostate Cancer ◽  
Dose Rate ◽  
Low Dose ◽  
Prostate Volume ◽  
Focal Therapy ◽  
Long Term Results ◽  
Prostate Brachytherapy ◽  
Psa Kinetics ◽  
Low Dose Rate ◽  
The Impact

151 Background: Prostate cancer patients continue to seek out minimally invasive therapies with equal disease eradication, but with less morbidity, lower cost and multiple salvage options. Our objective was to evaluate PSA response and determine rate of prostate specific antigen (PSA) kinetics in patients undergoing permanent low dose rate (LDR) focal prostate brachytherapy at a single institution. Methods: Between 4/2015 – 1/2017, 52 patients, of which 25% of patients were diagnosed with prostate cancer using a stereotactic transperineal mapping biopsy approach, while 75% had a standard transrectal prostate biopsy, were treated with LDR focal prostate brachytherapy. Dose to target was 115 Gy using Cesium-131. 30 patients (57.7%) were considered low risk, 21 pts (40.4%) were intermediate, and 1 patient (1.9%) was high risk. Treatment was limited to the side of the gland where the cancer was diagnosed. Because there is no agreed upon standard regarding PSA control, we are choosing to call the percent change in PSA the “Impact PSA”. Results: Median pre-treatment prostate volume was 51.6 cm3 (range 18 – 129 cm3), while the median target volume was 17.8 cm3 (range 7.6 – 39.4 cm3). Additionally, the median prostate volume treated was 33.73% (range 17.6 – 95.3%). Our data demonstrates that patients in whom 25-50% of the gland treated, resulted in an Impact PSA of approximately 25% - 50% decrease in total PSA between 3 - 6 months, with continued decreases of 55% at 1 year, and 77% at 2 years. Conclusions: Focal therapy outcomes are highly variable and related to volume of ablation. For low volume disease, LDR focal brachytherapy may be a viable option for patients. Optimal outcome assessment after focal therapy is yet to be determined. Since there is untreated gland with the potential to produce PSA, perhaps stable patterns in PSA kinetics, rather than a nadir, is more valuable. We will continue to follow-up with this cohort to report long term results and closely study the Impact PSA.

Sign in / Sign up

Export Citation Format

Share Document